Tag: gemtuzumab ozogamicin

Antibody–drug conjugates (ADCs) have transformed targeted cancer therapy by enabling the selective delivery of cytotoxic agents to tumor cells, sparing healthy tissue. The design of ADCs allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently considered the most promising drug classes in oncology, with ongoing efforts to expand their use for non-oncological indications and in combination therapies.

Bristol Myers Squibb (BMS) has acquired Orum Therapeutics’ ORM-6151 program, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase 1 for the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes.[1]

Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...

Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).

Over the last 40 years treatment of acute myeloid leukemia or AML has not significantly changed. Today, the standard of care for AML is treatment...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

The U.S. Food and Drug Administration (FDA) has approved gemtuzumab ozogamicin (Mylotarg™, previously known as CMA-676; Wyeth Pharmaceuticals, a subsidiary of Pfizer) for the...

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

From the Charlestown Navy Yard to the Paul Revere House, the Old State House on Washington Street, the New England Aquarium at Central Wharf...